Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy

被引：227

作者：

Goetz, Matthew P. ^{[1
]}

Sangkuhl, Katrin ^{[2
]}

Guchelaar, Henk-Jan ^{[3
]}

Schwab, Matthias ^{[4
,5
,6
]}

Province, Michael ^{[7
]}

Whirl-Carrillo, Michelle ^{[2
]}

Symmans, W. Fraser ^{[8
]}

McLeod, Howard L. ^{[9
]}

Ratain, Mark J. ^{[10
]}

Zembutsu, Hitoshi ^{[11
]}

Gaedigk, Andrea ^{[12
,13
]}

van Schaik, Ron H. ^{[14
,15
]}

Ingle, James N. ^{[1
]}

Caudle, Kelly E. ^{[16
]}

Klein, Teri E. ^{[2
]}

机构：

[1] Mayo Clin, Dept Oncol, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA

[2] Stanford Univ, Dept Biomed Data Sci, Stanford, CA 94305 USA

[3] Leiden Univ, Dept Clin Pharm & Toxicol, Med Ctr, Leiden, Netherlands

[4] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany

[5] Univ Hosp, Dept Clin Pharmacol, Tubingen, Germany

[6] Univ Tubingen, Dept Biochem & Pharm, Tubingen, Germany

[7] Washington Univ, Sch Med, Div Stat Genom, St Louis, MO USA

[8] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA

[9] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[10] Univ Chicago, Ctr Personalized Therapeut, Chicago, IL 60637 USA

[11] Natl Canc Ctr, Div Human Genet, Res Inst, Tokyo, Japan

[12] Univ Missouri, Div Clin Pharmacol Toxicol & Therapeut Innovat, Childrens Mercy Kansas City, Kansas City, MO 64110 USA

[13] Univ Missouri, Dept Pediat, Kansas City, MO 64110 USA

[14] Erasmus MC, Int Expertctr Pharmacogenet, Dept Clin Chem, Rotterdam, Netherlands

[15] LKCH UMC Utrecht, Utrecht, Netherlands

[16] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, 332 N Lauderdale St, Memphis, TN 38105 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2018年 / 103卷 / 05期

基金：

美国国家卫生研究院;

关键词：

BREAST-CANCER PATIENTS; ADJUVANT TAMOXIFEN; ESTROGEN-RECEPTOR; IN-VITRO; POSTMENOPAUSAL WOMEN; ACTIVE METABOLITE; CODEINE THERAPY; GENOTYPE; CYP2C19-ASTERISK-2; POLYMORPHISMS;

D O I：

10.1002/cpt.1007

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Tamoxifen is biotransformed by CYP2D6 to 4-hydroxytamoxifen and 4-hydroxy N-desmethyl tamoxifen (endoxifen), both with greater antiestrogenic potency than the parent drug. Patients with certain CYP2D6 genetic polymorphisms and patients who receive strong CYP2D6 inhibitors exhibit lower endoxifen concentrations and a higher risk of disease recurrence in some studies of tamoxifen adjuvant therapy of early breast cancer. We summarize evidence from the literature and provide therapeutic recommendations for tamoxifen based on CYP2D6 genotype.

引用

页码：770 / 777

页数：8

共 50 条

[1] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron
Bell, G. C.
Caudle, K. E.
Whirl-Carrillo, M.
Gordon, R. J.
Hikino, K.
Prows, C. A.
Gaedigk, A.
Agundez, J. A. G.
Sadhasivam, S.
Klein, T. E.
Schwab, M.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 102 (02) : 213 - 218
[2] Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update
Hicks, J. K.
Sangkuhl, K.
Swen, J. J.
Ellingrod, V. L.
Muller, D. J.
Shimoda, K.
Bishop, J. R.
Kharasch, E. D.
Skaar, T. C.
Gaedigk, A.
Dunnenberger, H. M.
Klein, T. E.
Caudle, K. E.
Stingl, J. C.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 102 (01) : 37 - 44
[3] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors
Hicks, J. K.
Bishop, J. R.
Sangkuhl, K.
Mueller, D. J.
Ji, Y.
Leckband, S. G.
Leeder, J. S.
Graham, R. L.
Chiulli, D. L.
LLerena, A.
Skaar, T. C.
Scott, S. A.
Stingl, J. C.
Klein, T. E.
Caudle, K. E.
Gaedigk, A.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 98 (02) : 127 - 134
[4] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy
Desta, Zeruesenay
Gammal, Roseann S.
Gong, Li
Whirl-Carrillo, Michelle
Gaur, Aditya H.
Sukasem, Chonlaphat
Hockings, Jennifer
Myers, Alan
Swart, Marelize
Tyndale, Rachel F.
Masimirembwa, Collen
Iwuchukwu, Otito F.
Chirwa, Sanika
Lennox, Jeffrey
Gaedigk, Andrea
Klein, Teri E.
Haas, David W.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 106 (04) : 726 - 733
[5] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype
Crews, K. R.
Gaedigk, A.
Dunnenberger, H. M.
Klein, T. E.
Shen, D. D.
Callaghan, J. T.
Kharasch, E. D.
Skaar, T. C.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 (02) : 321 - 326
[6] Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy
Crews, Kristine R.
Monte, Andrew A.
Huddart, Rachel
Caudle, Kelly E.
Kharasch, Evan D.
Gaedigk, Andrea
Dunnenberger, Henry M.
Leeder, J. Steven
Callaghan, John T.
Samer, Caroline Flora
Klein, Teri E.
Haidar, Cyrine E.
Van Driest, Sara L.
Ruano, Gualberto
Sangkuhl, Katrin
Cavallari, Larisa H.
Muller, Daniel J.
Prows, Cynthia A.
Nagy, Mohamed
Somogyi, Andrew A.
Skaar, Todd C.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 110 (04) : 888 - 896
[7] Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants
Hicks, J. K.
Swen, J. J.
Thorn, C. F.
Sangkuhl, K.
Kharasch, E. D.
Ellingrod, V. L.
Skaar, T. C.
Mueller, D. J.
Gaedigk, A.
Stingl, J. C.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 (05) : 402 - 408
[8] Interpreting the CYP2D6 Results From the International Tamoxifen Pharmacogenetics Consortium
Province, M. A.
Altman, R. B.
Klein, T. E.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 96 (02) : 144 - 146
[9] Considerations for the Utility of the CPIC Guideline for CYP2D6 Genotype and Codeine Therapy
Crews, Kristine R.
Caudle, Kelly E.
Dunnenberger, Henry M.
Sadhasivam, Senthilkumar
Skaar, Todd C.
CLINICAL CHEMISTRY, 2015, 61 (05) : 775 - 776
[10] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy
Moriyama, B.
Obeng, A. Owusu
Barbarino, J.
Penzak, S. R.
Henning, S. A.
Scott, S. A.
Agundez, J. A. G.
Wingard, J. R.
McLeod, H. L.
Klein, T. E.
Cross, S. J.
Caudle, K. E.
Walsh, T. J.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 102 (01) : 45 - 51

← 1 2 3 4 5 →